Top Back to top

RICMAC: Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study

Chronic Malignancies Working Party (CMWP)
Study number:
2005-002011-24
Type of transplant:
 
Short title:
RICMAC
Study status:
Completed Patient Recruitment
Deadline for data collection:
 
Study design:
Prospective randomised phase III multicentre study Primary objective
Primary objective:
The hypothesis that dose-reduces conditioning will reduce the non-rela'se mortality for 40% to 20% at one year after allogeneic stem cell transplantation​
Key inclusion criteria:
18-65 years old
Country:
Belgium
Finland
France
Germany
Italy
Russian Federation
Switzerland
Principal investigator:
Nicolaus Kröger
Principal investigator email:
 
EBMT Study coordinator:
Ruzena Uddin